Literature DB >> 1792462

Falsificationism and clinical trials.

S J Senn1.   

Abstract

The relevance of the philosophy of Sir Karl Popper to the planning, conduct and analysis of clinical trials is examined. It is shown that blinding and randomization can only be regarded as valuable for the purpose of refuting universal hypotheses. The purpose of inclusion criteria is also examined. It is concluded that a misplaced belief in induction is responsible for many false notions regarding clinical trials.

Mesh:

Year:  1991        PMID: 1792462     DOI: 10.1002/sim.4780101106

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

Review 1.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 2.  Plasma-derived medicines: access and usage issues.

Authors:  Albert Farrugia; Josephine Cassar
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

Review 3.  [The concept of therapeutic equivalence].

Authors:  S Lange; J Windeler
Journal:  Med Klin (Munich)       Date:  1997-04-15

Review 4.  A landmark for popperian epidemiology: refutation of the randomised Aldactone evaluation study.

Authors:  Elard Koch; Alvaro Otarola; Aida Kirschbaum
Journal:  J Epidemiol Community Health       Date:  2005-11       Impact factor: 3.710

5.  Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive.

Authors:  Andrew W Hahn; Nazli Dizman; Pavlos Msaouel
Journal:  Ther Adv Med Oncol       Date:  2022-06-01       Impact factor: 5.485

Review 6.  Evaluation of antiepileptic drug efficacy. A review of clinical trial design.

Authors:  G W Pledger; D Schmidt
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

7.  Effect of novel technology-enabled multidimensional physical activity feedback in primary care patients at risk of chronic disease - the MIPACT study: a randomised controlled trial.

Authors:  Oliver J Peacock; Max J Western; Alan M Batterham; Enhad A Chowdhury; Afroditi Stathi; Martyn Standage; Alan Tapp; Paul Bennett; Dylan Thompson
Journal:  Int J Behav Nutr Phys Act       Date:  2020-08-08       Impact factor: 6.457

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.